118 related articles for article (PubMed ID: 18335219)
1. Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Font A; Salazar R; Maurel J; Taron M; Ramirez JL; Tabernero J; Gallego R; Casado E; Manzano JL; Carcereny E; Guix M; Fernández-Llamazares J; Rosell R
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1075-83. PubMed ID: 18335219
[TBL] [Abstract][Full Text] [Related]
2. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
[TBL] [Abstract][Full Text] [Related]
3. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer.
Provencio M; Camps C; Cobo M; De las Peñas R; Massuti B; Blanco R; Alberola V; Jimenez U; Delgado JR; Cardenal F; Tarón M; Ramírez JL; Sanchez A; Rosell R
Cancer Chemother Pharmacol; 2012 Dec; 70(6):883-90. PubMed ID: 23053267
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
Iranzo V; Sirera R; Bremnes RM; Blasco A; Jantus-Lewintre E; Tarón M; Berrocal A; Blasco S; Caballero C; Del Pozo N; Rosell R; Camps C
Clin Lung Cancer; 2011 Jul; 12(4):224-30. PubMed ID: 21726821
[TBL] [Abstract][Full Text] [Related]
5. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Earle CC; Kulke MH; Meyerhardt JA; Blaszkowsky LS; Zhu AX; Fidias P; Vincitore MM; Mayer RJ; Fuchs CS
Ann Oncol; 2009 Mar; 20(3):475-80. PubMed ID: 19139178
[TBL] [Abstract][Full Text] [Related]
6. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
7. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
[TBL] [Abstract][Full Text] [Related]
9. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.
Giovannetti E; Pacetti P; Reni M; Leon LG; Mambrini A; Vasile E; Ghidini M; Funel N; Lucchesi M; Cereda S; Peters GJ; Cantore M
Pharmacogenomics; 2011 Dec; 12(12):1641-52. PubMed ID: 22026922
[TBL] [Abstract][Full Text] [Related]
10. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.
Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
Cancer; 2002 Feb; 94(3):641-6. PubMed ID: 11857295
[TBL] [Abstract][Full Text] [Related]
11. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma.
Polyzos A; Syrigos K; Stergiou J; Panopoulos C; Potamianou A; Vamvakas L; Georgoulias V
Cancer Chemother Pharmacol; 2005 May; 55(5):466-70. PubMed ID: 15660272
[TBL] [Abstract][Full Text] [Related]
14. XRCC3 Thr241Met and XPD Lys751Gln gene polymorphisms and risk of clear cell renal cell carcinoma.
Loghin A; Bănescu C; Nechifor-Boila A; Chibelean C; Orsolya M; Nechifor-Boila A; Tripon F; Voidazan S; Borda A
Cancer Biomark; 2016; 16(2):211-7. PubMed ID: 26682510
[TBL] [Abstract][Full Text] [Related]
15. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.
Shirao K; Shimada Y; Kondo H; Saito D; Yamao T; Ono H; Yokoyama T; Fukuda H; Oka M; Watanabe Y; Ohtsu A; Boku N; Fujii T; Oda Y; Muro K; Yoshida S
J Clin Oncol; 1997 Mar; 15(3):921-7. PubMed ID: 9060529
[TBL] [Abstract][Full Text] [Related]
16. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
Li P; Wang YD; Cheng J; Chen JC; Ha MW
Tumour Biol; 2015 Dec; 36(12):9465-73. PubMed ID: 26124006
[TBL] [Abstract][Full Text] [Related]
17. A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer.
Brenner B; Sarfaty M; Purim O; Kundel Y; Amit L; Abramovich A; Sadeh Gonik U; Idelevich E; Gordon N; Medalia G; Sulkes A
PLoS One; 2016; 11(7):e0157548. PubMed ID: 27390847
[TBL] [Abstract][Full Text] [Related]
18. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Chen X; Sun H; Ren S; Kim Curran V; Zhang L; Zhou S; Zhang J; Zhou C
Clin Transl Oncol; 2012 Mar; 14(3):207-13. PubMed ID: 22374424
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]